Head-To-Head Review: Viking Therapeutics (NASDAQ:VKTX) versus Its Competitors

Viking Therapeutics (NASDAQ: VKTX) is one of 285 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it compare to its rivals? We will compare Viking Therapeutics to similar companies based on the strength of its institutional ownership, profitability, earnings, analyst recommendations, risk, dividends and valuation.

Risk and Volatility

Viking Therapeutics has a beta of 1.87, indicating that its stock price is 87% more volatile than the S&P 500. Comparatively, Viking Therapeutics’ rivals have a beta of 1.63, indicating that their average stock price is 63% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Viking Therapeutics and its rivals, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Viking Therapeutics 0 0 3 0 3.00
Viking Therapeutics Competitors 843 3191 11569 230 2.71

Viking Therapeutics presently has a consensus target price of $7.00, suggesting a potential upside of 145.61%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 44.63%. Given Viking Therapeutics’ stronger consensus rating and higher probable upside, research analysts plainly believe Viking Therapeutics is more favorable than its rivals.

Valuation & Earnings

This table compares Viking Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Viking Therapeutics N/A -$14.73 million -3.39
Viking Therapeutics Competitors $284.30 million $34.29 million 135.48

Viking Therapeutics’ rivals have higher revenue and earnings than Viking Therapeutics. Viking Therapeutics is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

7.5% of Viking Therapeutics shares are held by institutional investors. Comparatively, 50.3% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 8.2% of Viking Therapeutics shares are held by company insiders. Comparatively, 16.6% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Viking Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Viking Therapeutics N/A -330.42% -144.29%
Viking Therapeutics Competitors -5,266.10% -428.13% -38.73%

About Viking Therapeutics

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery. VK5211 is a non-steroidal selective androgen receptor modulator (SARM). Its second program is focused on the development of orally available small molecule thyroid hormone receptor beta agonists. Its two molecules are VK2809 and VK0214. VK2809 is an orally available, tissue and receptor-subtype selective agonist of the thyroid beta receptor that is entering Phase II development for the treatment of patients with hypercholesterolemia and fatty liver disease. It is developing VK0214 for the treatment of X-linked adrenoleukodystrophy (X-ALD). It has a pipeline with approximately three additional programs targeting metabolic diseases and anemia.

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply